Author:
Skowron Gail,Chowdhry Sapna,Stevens Michael R.
Reference212 articles.
1. Mitsuya H, Broder, S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLVIII/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83(6):1911–1915.
2. Squires KE, Gulick, R, Tebas P et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000;14(11):1591–1600.
3. Eron JJ Jr, Murphy RL, Peterson D et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000;14(11):1601–1610.
4. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292(2):191–201.
5. Gottlieb M, Peterson D, Adler M Comparison of safety and efficacy of two doses of stavudine (Zerit, d4T) in a large simple trial in the US Parallel Track Program[abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献